{"slideshow_credits": null, "snippet": "The Healthcare Supply Chain Association says the backlog of new generic drug applications at the F.D.A. is compounding the problem of price increases.", "abstract": null, "section_name": "Opinion", "print_page": null, "document_type": "article", "byline": [], "web_url": "http://www.nytimes.com/2016/05/19/opinion/the-generic-drug-market.html", "lead_paragraph": "The Healthcare Supply Chain Association says the backlog of new generic drug applications at the F.D.A. is compounding the problem of price increases.", "headline": {"main": "The Generic Drug Market", "content_kicker": "Letter", "kicker": "Letter"}, "_id": "573c916038f0d86c87c2cefb", "word_count": "255", "multimedia": [], "pub_date": "2016-05-19T00:00:00Z", "source": "The New York Times", "news_desk": "Letters", "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "1"}, {"name": "subject", "value": "Generic Brands and Products", "is_major": "N", "rank": "2"}], "blog": [], "subsection_name": null, "type_of_material": "Letter"}